Detalhe

Produções afetadas
Endereço - Univ Campinas SP
1)
PT
J
TI
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic
myeloid leukemia in chronic phase
DT
Article
ID
TYROSINE KINASE INHIBITORS; CHRONIC MYELOGENOUS LEUKEMIA; FOLLOW-UP; PHILADELPHIA-CHROMOSOME;
EUROPEAN LEUKEMIANET; SELECTIVE INHIBITOR; CLINICAL RESISTANCE; DOMAIN MUTATIONS; THERAPY; CML
C1
[Hochhaus, Andreas] Univ Klinikum Jena, Abt Hamatol Onkol, D-07740 Jena, Germany.
[Saglio, Giuseppe] Univ Turin, San Luigi Gonzaga Hosp, Orbassano, Italy.
[Larson, Richard A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Kim, Dong-Wook] Catholic Univ Korea, St Marys Hosp, Seoul, South Korea.
[Etienne, Gabriel] Inst Bergonie, Bordeaux, France.
[Rosti, Gianantonio] Univ Bologna, Inst L&A Seragnoli, Bologna, Italy.
[De Souza, Carmino] Univ Campinas SP, UNICAMP, Campinas, SP, Brazil.
[Kurokawa, Mineo] Tokyo Univ Hosp, Tokyo 113, Japan.
[Kalaycio, Matt E.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
[Hoenekopp, Albert] Novartis Pharma AG, Basel, Switzerland.
[Fan, Xiaolin; Shou, Yaping] Novartis Pharmaceut, E Hanover, NJ USA.
[Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Hughes, Timothy P.] Univ Adelaide, SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia.
PY
2013
ER
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------2)
PT
J
TI
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vsimatinib in patients with newly diagnosed chronic
myeloid leukemia inchronic phase
DT
Article
ID
TYROSINE KINASE INHIBITORS; CHRONIC MYELOGENOUS LEUKEMIA; FOLLOW-UP;PHILADELPHIA-CHROMOSOME;
EUROPEAN LEUKEMIANET; SELECTIVE INHIBITOR;CLINICAL RESISTANCE; DOMAIN MUTATIONS; THERAPY; CML
C1
[Hochhaus, Andreas] Univ Klinikum Jena, Abt Hamatol Onkol, D-07740 Jena, Germany.
[Saglio, Giuseppe] Univ Turin, San Luigi Gonzaga Hosp, Orbassano, Italy.
[Larson, Richard A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Kim, Dong-Wook] Catholic Univ Korea, St Marys Hosp, Seoul, South Korea.
[Etienne, Gabriel] Inst Bergonie, Bordeaux, France.
[Rosti, Gianantonio] Univ Bologna, Inst L&A Seragnoli, Bologna, Italy.
[De Souza, Carmino] Univ Campinas SP, UNICAMP, Campinas, SP, Brazil.
[Kurokawa, Mineo] Tokyo Univ Hosp, Tokyo 113, Japan.
[Kalaycio, Matt E.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
[Hoenekopp, Albert] Novartis Pharma AG, Basel, Switzerland.
[Fan, Xiaolin; Shou, Yaping] Novartis Pharmaceut, E Hanover, NJ USA.
[Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Hughes, Timothy P.] Univ Adelaide, SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia.
PY
2013
ER
30/09/2016
UNICAMP / Centro de Computação
Página 1 / 1